Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ
303.53
-4.29 (-1.39%)
Closed
Oct 23, 2026
Day's Range
302.37313.28
52 wk Range
175.89326.63
Financial Statements - LGND - Ligand Pharmaceuticals Incorporated
Revenue
268.08M▲ 60.4%
Net Income
124.45M▲ 3186.6%Net Margin 46.4%
EBITDA
94.54M▲ 729.6%
Free Cash Flow
38.04M▼ 50.9%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 268.08M | 167.13M | 131.31M | 196.24M | 241.54M | 163.56M |
| Cost of Goods | 14.54M | 11.07M | 10.51M | 52.82M | 62.17M | 30.41M |
| Gross Profit | 253.53M | 156.05M | 120.80M | 143.41M | 179.36M | 133.14M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 47.19M | 23.02M | 9.82M | 3.03M | 103.85M | 20.38M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 102.81M | -25.52M | 46.78M | 32.72M | -12.91M | 243K |
| Pre Tax Income | 158.96M | 2.51M | 63.66M | 36.01M | 72.20M | 1.29M |
| Income Tax | 34.50M | 6.55M | 9.84M | 41.23M | -4.14M | -5.30M |
| Net Income | 124.45M | -4.03M | 52.15M | -33.36M | 57.13M | -2.98M |
| EPS Basic | 6.44 | -0.22 | 3.02 | -1.98 | 3.46 | -0.18 |
| EPS Diluted | 6.13 | -0.22 | 2.94 | -1.98 | 3.34 | -0.18 |
| Basic Shares Outstanding | 19.33M | 18.29M | 17.29M | 16.86M | 16.63M | 16.18M |
| Diluted Shares Outstanding | 19.33M | 18.29M | 17.29M | 16.86M | 16.63M | 16.18M |
| Ebit | 163.67M | 5.55M | 64.31M | 37.81M | 91.82M | 28.70M |
| Ebitda | 94.54M | 11.39M | 51.22M | 60.64M | 148.03M | 56.49M |
| Net Income Continuous Operations | 124.45M | -4.03M | 52.15M | -33.36M | 57.13M | -2.98M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
